CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
8 results
Search Results
Now showing 1 - 8 of 8
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Excess burden of antibiotic-resistant bloodstream infections: evidence from a multicentre retrospective cohort study in Chile, 2018–2022(2024) ;Kasim Allel ;Anne Peters ;Hassan Haghparast-Bidgoli ;Maria Spencer-SandinoJose ConejerosScopus© Citations 2 4 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 10Scopus© Citations 44 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Multisite Detection of Tn
<i>1549</i>
-Mediated
<i>vanB</i>
Vancomycin Resistance in Multidrug-Resistant Enterococcus faecalis ST6 in Texas and Florida(2023) ;Shelby R. Simar ;Truc T. Tran ;Kirsten B. Rydell ;Diana PanessoGerman A. Contreras<jats:p> In the United States, <jats:italic>vanB</jats:italic> -mediated resistance in enterococci is rare. We characterized three sequence type (ST) 6, vancomycin-resistant <jats:named-content content-type="genus-species">Enterococcus faecalis</jats:named-content> isolates causing bacteremia in unique patients in spatiotemporally distinct settings. </jats:p>7 1Scopus© Citations 3 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antimicrobial Susceptibility Testing for Enterococci(2022) ;Ayesha Khan ;William R. Miller ;Dierdre Axell-House; Cesar A. Arias<jats:p>Enterococci are major, recalcitrant nosocomial pathogens with a wide repertoire of intrinsic and acquired resistance determinants and the potential of developing resistance to all clinically available antimicrobials. As such, multidrug-resistant enterococci are considered a serious public health threat.</jats:p>1Scopus© Citations 57 1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)(2021) ;German A Contreras; ;Shelby Simar ;Courtney LuterbachAn Q Dinh<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Vancomycin-resistant enterococci (VRE) are major therapeutic challenges. Prospective contemporary data characterizing the clinical and molecular epidemiology of VRE bloodstream infections (BSIs) are lacking.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>The Vancomycin-Resistant Enterococcal BSI Outcomes Study (VENOUS I) is a prospective observational cohort of adult patients with enterococcal BSI in 11 US hospitals. We included patients with Enterococcus faecalis or Enterococcus faecium BSI with ≥1 follow-up blood culture(s) within 7 days and availability of isolate(s) for further characterization. The primary study outcome was in-hospital mortality. Secondary outcomes were mortality at days 4, 7, 10, 12, and 15 after index blood culture. A desirability of outcome ranking was constructed to assess the association of vancomycin resistance with outcomes. All index isolates were subjected to whole genome sequencing.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Forty-two of 232 (18%) patients died in hospital and 39 (17%) exhibited microbiological failure (lack of clearance in the first 4 days). Neutropenia (hazard ratio [HR], 3.13), microbiological failure (HR, 2.4), VRE BSI (HR, 2.13), use of urinary catheter (HR, 1.85), and Pitt BSI score ≥2 (HR, 1.83) were significant predictors of in-hospital mortality. Microbiological failure was the strongest predictor of in-hospital mortality in patients with E faecium bacteremia (HR, 5.03). The impact of vancomycin resistance on mortality in our cohort changed throughout the course of hospitalization. Enterococcus faecalis sequence type 6 was a predominant multidrug-resistant lineage, whereas a heterogeneous genomic population of E faecium was identified.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Failure of early eradication of VRE from the bloodstream is a major factor associated with poor outcomes.</jats:p> </jats:sec>5Scopus© Citations 42 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 7Scopus© Citations 553 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Scopus© Citations 170 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, What's New in the Treatment of Enterococcal Endocarditis?(2014) ;Masayuki Nigo; ;Cesar A. AriasBarbara E. Murray27Scopus© Citations 49